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The rapidity with which COVID-19 spread across the
world left governments with little time to respond.
Now, however, as some countries see a flattening or
even a decline in deaths, many are considering what a
sustainable exit strategy might look like.1 Ultimately,
this will require a safe and effective vaccine, coupled
with new treatment for those who remain unpro-
tected. For now, however, the emphasis has been
on driving the transmission number, or R0, below
1, so that each infected person spreads the disease
to fewer than one other on average, and keeping it
there with continuing restrictions on large gatherings,
social distancing in everyday life and, increasingly,
use of face coverings. However, it is also important
that any exit strategy considers the broader
health, economic and public policy implications of
COVID-19.
From a health perspective, there are short- to
medium-term implications. At least some of the
excess deaths during the pandemic have been due to
a failure to seek necessary urgent care. A large
increase in weekly deaths out of hospital where
COVID-19 is not listed on the death certificate is
likely, in part, to be due to underdiagnosis but has
occurred at the same time as substantial declines in
those attending hospital with acute coronary syn-
drome and strokes.2 Attendances in primary care
have also declined and widespread cancellations of
elective surgery have delayed surgeries for patients
with cancer,3 while those with coronary occlusions
have also seen procedures postponed.4 Treatment
algorithms have been adjusted to deliver sub-optimal
treatments such as shorter durations of chemother-
apy,3 or thrombolysis instead of percutaneous coron-
ary intervention.5 As a consequence, there will be a
large reservoir of unmet need, some of which will
have caused conditions to deteriorate, necessitating
additional or more complex treatment.6 Exit
strategies must capitalise upon periods of relative
suppression of COVID-19 to ensure that those
affected are identified and receive care, with priori-
tisation given to those with highest clinical need.
Mental health, so often hidden, is a particular con-
cern as social isolation has increased loneliness,
depression and anxiety.7 People with substance
misuse problems have suffered, as access to addiction
support services has been restricted.8 Health workers
are being exposed to traumatic experiences on a daily
basis, which require early support and after care to
protect against long-term mental health conse-
quences.9 Finally, action will be needed to support
those who have experienced domestic violence who
have struggled to access safe havens.10
From an economic perspective, there will be a need
to ensure a rapid but sustainable recovery. The
International Monetary Fund estimates a 6.1%
decline in gross domestic product in advanced econo-
mies in 2020,11 although other analyses suggest the
decline could be greater. Estimates from Germany
suggest that a one-month lockdown would cost
between 4.3% and 7.5% of gross domestic product
(E150–260 billion), and a three-month lockdown
would cost between 10% and 20.6% of gross domes-
tic product (E354–729 billion).12 Some politicians are
arguing that the scale of the economic harm justifies
lifting restrictions earlier but this view does not with-
stand serious scrutiny. Few people will be willing to
engage in normal activities such as eating out or
attending entertainment venues if the death toll is
accelerating upwards and healthcare systems, which
they may need for non-COVID-19 conditions, are
being overwhelmed.13 It will be important to ensure
that companies, and especially the small and medium
ones that are the engine of many local economies, are
able to respond rapidly to the progressive lifting of
restrictions. This means that governments must take
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large-scale measures to tide them over, providing
interest-free loans, salary support for furloughed
workers and delaying tax demands among others.14
It will also be important to put in place measures to
protect them from speculators who are already seek-
ing to undermine long-established but now vulner-
able companies, especially those that have stepped
up to help the struggle against COVID-19.15
Finally, as some politicians such as President
Macron have noted, this pandemic is an opportunity
to do things differently. The spread of infection has
been facilitated in many countries by a long-term dis-
investment in public services, and especially public
health. There has been a realisation that the workers
who are really essential to the functioning of society
are those who, in the past, have been valued least.
This must change.
From a public policy perspective, there are several
challenges to navigate. First, countries are using tech-
nologies in novel ways to ease social distancing meas-
ures that may impinge upon civil liberties. For
example, China is using an app to monitor people’s
movement, classifying them according to their health
status and travel history.16 A similar app has been
suggested in Germany.17 This raises ethical questions
about the legitimate role of state intervention in
restricting freedom of movement, and privacy con-
cerns about the storage and use of data, concerns
intensified by how some politicians, such as
Hungary’s Victor Orbán, have exploited the crisis
to suspend democratic processes.18 Second, it will
be important to recognise that, while the burden of
premature death has fallen most on older people, it is
younger people whose finances and employment
opportunities will be affected disproportionately.
Given that some degree of separation may continue
for some time, for example designating spaces or
earmarked times in shops and supermarkets for vul-
nerable and elderly people, it will be important to
pre-empt intergenerational tensions. Third, efforts
to combat COVID-19 continue to be plagued by
fake news. One high-profile and damaging example
has been premature claims about the effectiveness of
chloroquine in treating COVID-19, leading to stock-
piling and cases of chloroquine poisoning.19 France’s
drug-safety agency has linked chloroquine to adverse
cardiac events in patients with COVID-19,20 and a
trial of the drug in Brazil had to be stopped for the
same reason.21 Social media companies will need to
be diligent, and act appropriately even when leading
figures spread misinformation. For example, Twitter
and Facebook were recently quick to remove posts
from Brazilian President Jair Bolsonaro,22 although
Twitter declined to do the same when President
Trump posted messages that were interpreted as
undermining state policies on social distancing.23
Lastly, there is a tension between national and
global governance.24 There is no clear mechanism
to deal with a country that refuses to adopt policies
to contain the spread of infection, even though its
actions pose a threat to the rest of the world.
A sustainable exit strategy must be based on the
epidemiology of COVID-19 but must go beyond it. It
has been politically challenging to implement social
distancing measures, but technically simple. In con-
trast, because of limited evidence, easing social dis-
tancing measures will be technically more
challenging. In reality, this will be a process of trial
and error. We will have to learn from each other and
bear in mind that there will be challenged in translat-
ing the emerging evidence across different national
contexts. We must not forget that a decade of auster-
ity has left healthcare systems under-resourced and
exposed. Future planning must include sustainable
funding and building resilience to prepare for any
potential major future health threats.
Declarations
Competing Interests: None declared.
Funding: None declared.
Ethics approval: Not applicable.
Guarantor: MA.
Contributorship: MA wrote and finalised the article. MM and
EM revised the draft and provided critical feedback. The final
version of the article was approved by all authors.
Acknowledgements: None.
Provenance: Not commissioned; editorial review




1. McKee M. A European roadmap out of the covid-19
pandemic. BMJ 2020; 369: m1556. DOI:10.1136/
bmj.m1556.
2. Spinney L. Concern as heart attack and stroke patients
delay seeking help. The Guardian, 16 April 2020. See
http://www.theguardian.com/world/2020/apr/16/coro-
navirus-concern-heart-attack-stroke-patients-delay-
seeking-help (last checked 18 April 2020).
3. Burki TK. Cancer guidelines during the COVID-19 pan-
demic. Lancet Oncol. Epub ahead of print 2 April 2020.
DOI:10.1016/S1470-2045(20)30217-5.
4. CMS. CMS Adult Elective Surgery and Procedures
Recommendations: Limit All Non-essential Planned
Surgeries and Procedures, Including Dental, Until
Further Notice. See https://www.cms.gov/files/docu-
ment/31820-cms-adult-elective-surgery-and-procedures-
recommendations.pdf (last checked 18 April 2020).
Anderson et al. 177
5. Zeng J, Huang J and Pan L. How to balance acute
myocardial infarction and COVID-19: the protocols
from Sichuan Provincial People’s Hospital. Intensive
Care Med. Epub ahead of print March 11 2020.
DOI:10.1007/s00134-020-05993-9.
6. Carter P, Anderson M and Mossialos E. Health
system, public health and economic implications of
managing COVID-19 from a cardiovascular perspec-
tive. Eur Heart J 2020; ehaa342. DOI:10.1093/eur-
heartj/ehaa342.
7. Armitage R and Nellums LB. COVID-19 and the con-
sequences of isolating the elderly. Lancet Public Health.
Epub ahead of print 20 March 2020. DOI:10.1016/
S2468-2667(20)30061-X.
8. European Monitoring Centre for Drugs and Drug
Addiction. EMCDDA Update on the Implications of
COVID-19 for People Who Use Drugs (PWUD) and
Drug Service Providers. See http://www.emcdda.
europa.eu/system/files/publications/12879/emcdda-
covid-update-1-25.03.2020v2.pdf (last checked 18 April
2020).
9. Greenberg N, Docherty M, Gnanapragasam S and
Wessely S. Managing mental health challenges faced
by healthcare workers during covid-19 pandemic.
BMJ 2020; 368: m1211. DOI:10.1136/bmj.m1211.
10. Taub A. A new Covid-19 crisis: domestic abuse rises
worldwide. The New York Times, 6 April 2020. See
https://www.nytimes.com/2020/04/06/world/corona-
virus-domestic-violence.html (last checked 18 April
2020).
11. International Monetary Fund. World Economic
Outlook, Chapter 1: The Great Lockdown. See https://
www.imf.org/en/Publications/WEO/Issues/2020/04/14/
weo-april-2020 (last checked 18 April 2020).
12. The German Institute for Economic Research. Making
the Fight Against the Coronavirus Pandemic
Sustainable. See https://www.ifo.de/en/publikationen/
2020/monograph-authorship/making-fight-against-cor-
onavirus-pandemic-sustainable (last checked 18 April
2020).
13. Ferguson N, Laydon D, Nedjati Gilani G, et al. Report
9: impact of non-pharmaceutical interventions (NPIs)
to reduce COVID19 mortality and healthcare demand.




checked 18 April 2020).
14. McKee M and Stuckler D. If the world fails to protect
the economy, COVID-19 will damage health not just
now but also in the future. Nature Med 2020. DOI:
10.1038/s41591-020-0863-y.
15. Geoghegan P. As Burberry makes PPE for nurses and




stock/ (last checked 18 April 2020).
16. Davidson H. China’s coronavirus health code apps
raise concerns over privacy. The Guardian, 1 April
2020. See http://www.theguardian.com/world/2020/
apr/01/chinas-coronavirus-health-code-apps-raise-con-
cerns-over-privacy (last checked 18 April 2020).
17. 2nd Ad-hoc-Statement: Coronavirus Pandemic –
Measures Relevant to Health. 2020. See https://www.
leopoldina.org/uploads/tx_leopublication/2020_04_
08_2ad_hoc_statement_coronavirus_en_final_01.pdf
(last checked 18 April 2020).
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